UA29437C2 - (s)-альфа-феніл-2-піридинетанамін або його сіль з неорганічною кислотою, які мають протисудомну активність, спосіб їх отримання, лікарський препарат на їх основі та спосіб лікування судом - Google Patents

(s)-альфа-феніл-2-піридинетанамін або його сіль з неорганічною кислотою, які мають протисудомну активність, спосіб їх отримання, лікарський препарат на їх основі та спосіб лікування судом

Info

Publication number
UA29437C2
UA29437C2 UA94095853A UA94095853A UA29437C2 UA 29437 C2 UA29437 C2 UA 29437C2 UA 94095853 A UA94095853 A UA 94095853A UA 94095853 A UA94095853 A UA 94095853A UA 29437 C2 UA29437 C2 UA 29437C2
Authority
UA
Ukraine
Prior art keywords
medicament
treatment
pyridinetamine
convulsions
phenyl
Prior art date
Application number
UA94095853A
Other languages
English (en)
Russian (ru)
Inventor
Рональд Конрад Гріффіт
Рональд Конрад Гриффит
Роберт Джон Мюррей
Майкл Бейлестра
Original Assignee
Астра АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Астра АБ filed Critical Астра АБ
Publication of UA29437C2 publication Critical patent/UA29437C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Винахід описує енантіомер відомої сполуки. Воно стосується також його використання як лікарського засобу для лікування нейродегенеративних розладів.
UA94095853A 1992-04-03 1993-04-01 (s)-альфа-феніл-2-піридинетанамін або його сіль з неорганічною кислотою, які мають протисудомну активність, спосіб їх отримання, лікарський препарат на їх основі та спосіб лікування судом UA29437C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
UA29437C2 true UA29437C2 (uk) 2000-11-15

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94095853A UA29437C2 (uk) 1992-04-03 1993-04-01 (s)-альфа-феніл-2-піридинетанамін або його сіль з неорганічною кислотою, які мають протисудомну активність, спосіб їх отримання, лікарський препарат на їх основі та спосіб лікування судом

Country Status (29)

Country Link
EP (1) EP0633879B1 (uk)
JP (2) JP3120810B2 (uk)
KR (1) KR100259567B1 (uk)
CN (1) CN1044367C (uk)
AT (1) ATE163925T1 (uk)
AU (2) AU3897693A (uk)
CA (1) CA2133427C (uk)
CZ (1) CZ288519B6 (uk)
DE (1) DE69317411T2 (uk)
DK (1) DK0633879T3 (uk)
DZ (1) DZ1677A1 (uk)
ES (1) ES2115055T3 (uk)
FI (1) FI105025B (uk)
HK (1) HK1009331A1 (uk)
HU (1) HU211529A9 (uk)
IL (1) IL105276A (uk)
MA (1) MA22866A1 (uk)
MX (1) MX9301935A (uk)
MY (1) MY110149A (uk)
NO (1) NO302170B1 (uk)
NZ (1) NZ251384A (uk)
PL (1) PL180014B1 (uk)
RU (1) RU2128650C1 (uk)
SG (1) SG47948A1 (uk)
SK (1) SK281258B6 (uk)
TW (1) TW282455B (uk)
UA (1) UA29437C2 (uk)
WO (1) WO1993020052A1 (uk)
ZA (1) ZA932415B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
EP0356035B1 (en) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
CA2748235A1 (en) * 2008-12-24 2010-07-01 Astrazeneca Ab Ethanamine compounds and their use for treating depression
EP2791352A1 (en) 2011-12-14 2014-10-22 Astrazeneca AB Gabr-a2 diagnostic
TR201909632T4 (tr) * 2013-11-05 2019-07-22 Astrazeneca Ab Nmda antagonisti ön ilaçları.
US20230190719A1 (en) * 2020-06-23 2023-06-22 Biohaven Therapeutics Ltd. Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356035B1 (en) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties

Also Published As

Publication number Publication date
FI105025B (fi) 2000-05-31
JPH07505385A (ja) 1995-06-15
IL105276A (en) 1997-06-10
DE69317411D1 (de) 1998-04-16
ZA932415B (en) 1993-10-22
EP0633879B1 (en) 1998-03-11
KR100259567B1 (ko) 2000-07-01
NO943645L (no) 1994-11-16
HU211529A9 (en) 1995-11-28
FI944546A (fi) 1994-09-30
DK0633879T3 (da) 1998-09-28
AU3897693A (en) 1993-11-08
CN1044367C (zh) 1999-07-28
MX9301935A (es) 1994-08-31
CA2133427A1 (en) 1993-10-14
NO943645D0 (no) 1994-09-30
AU7545696A (en) 1997-02-13
TW282455B (uk) 1996-08-01
WO1993020052A1 (en) 1993-10-14
RU94042465A (ru) 1996-07-20
CN1081669A (zh) 1994-02-09
HK1009331A1 (en) 1999-05-28
DE69317411T2 (de) 1998-07-30
FI944546A0 (fi) 1994-09-30
MA22866A1 (fr) 1993-12-31
AU705419B2 (en) 1999-05-20
NO302170B1 (no) 1998-02-02
SK281258B6 (sk) 2001-01-18
JP2000319259A (ja) 2000-11-21
EP0633879A1 (en) 1995-01-18
CZ288519B6 (cs) 2001-07-11
ES2115055T3 (es) 1998-06-16
ATE163925T1 (de) 1998-03-15
CA2133427C (en) 2003-06-10
IL105276A0 (en) 1993-08-18
PL180014B1 (pl) 2000-11-30
SG47948A1 (en) 1998-04-17
MY110149A (en) 1998-02-28
SK117794A3 (en) 1995-05-10
CZ240994A3 (en) 1995-12-13
DZ1677A1 (fr) 2002-02-17
NZ251384A (en) 1996-10-28
JP3120810B2 (ja) 2000-12-25
RU2128650C1 (ru) 1999-04-10

Similar Documents

Publication Publication Date Title
EP1014881A4 (en) TREATMENT OF NEURODEGENERATIVE CONDITIONS BY INFUSION OF NERVOUS GROWTH FACTORS IN THE BRAIN
IL119839A0 (en) Process for the preparation of D.L-methionine or the salt thereof
MY140557A (en) Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
AU3056297A (en) Techniques of treating neurodegenerative disorders by brain infusion
CA2207289A1 (en) Supplemented and unsupplemented tissue sealants, methods of their production and use
IL127244A0 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
CA2391808A1 (en) Method for treatment of symptoms of central nervous system disorders
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
WO1994027587A3 (en) Sustained antiepileptic therapy
ZA9711279B (en) Method for treating and preventing neurological disorders and promoting wound healing.
UA29437C2 (uk) (s)-альфа-феніл-2-піридинетанамін або його сіль з неорганічною кислотою, які мають протисудомну активність, спосіб їх отримання, лікарський препарат на їх основі та спосіб лікування судом
EP0723460A4 (en) GENE THERAPY FOR THE NERVOUS SYSTEM
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
MY129130A (en) (+)-norcisapride
AU4372597A (en) Method for the treatment of neurological or neuropsychiatric disorders
AU1447095A (en) Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
GB9412469D0 (en) Fungicidal seed treatment using phosphorous acid or its salt
GB2271990B (en) Process for the preparation of L-5-(2-acetoxy-propionylamino)--2,4,6-triiodo-isophthalic acid dichloride
IE821172L (en) Anticonvulsant benzamides
AU7654298A (en) A method for the improvement of neuronal regeneration
NO934211D0 (no) Belagt titandioksyd, samt fremgangsm}te for fremstilling derav
HK1038510A1 (en) Use of neurotrophic factor stimulators for the treamtent of ophthalmic neurodegenerative diseases.
ZA968550B (en) Novel processes for the preparation of anti-malarial compounds.
DE59301021D1 (de) Verfahren zur kontinuierlichen Herstellung von 3-Cyano-3,5,5-trimethylcyclohexanon.